Who owns Cogent Biosciences, Inc. (COGT)? Elite investor 13F holders

4 tracked elite investors reported holding Cogent Biosciences, Inc as of 2026-09-30, including Renaissance Technologies LLC, D.E. Shaw, Oaktree Capital Management, Polen Capital Management. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.

4 tracked investors currently reported holding · Latest report period: 2026-09-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences

Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well…

Reported holders and securities, including exits (up to 20)

Reported holders and securities, including exits (up to 20)
InvestorSecurityInstrumentReport periodFiledValueQuantityUnitsChangeSource
Renaissance Technologies LLCCogent Biosciences IncSHARE2026-09-302026-11-12 00:00:0022691549.00 USD708668.000000SharesreduceOriginal filing
D.E. ShawCogent Biosciences IncSHARE2026-09-302026-11-16 00:00:0013003386.00 USD406102.000000SharesreduceOriginal filing
Oaktree Capital ManagementCOGENT BIOSCIENCES INCSHARE2026-06-302026-08-14 00:00:0014758452.00 USD11890000.000000PrincipaladdOriginal filing
Polen Capital ManagementCogent Biosciences IncSHARE2026-09-302026-11-13 00:00:001151920.00 USD35975.000000SharesbuyOriginal filing

Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.

This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.

How to read the data · Disclaimer

Read as Markdown